/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | AVBPArriVent BioPharma, |
|---|---|
| Last close | $15.36 |
| Change % | -26.86% |
| Market cap | $757M |
| P/E | — |
| Revenue | — |
| Rev growth (YoY) | — |
| Net income | $-166308000 |
| Net margin | — |
| EPS (diluted) | $-4.32 |
| Piotroski F-ScoreUNVALIDATED | — |
| Altman Z-ScoreUNVALIDATED | — |
| Beneish M-ScoreUNVALIDATED | — |
| Next earnings | 11-04 → 11-14 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Green = best in the row among the compared names. Educational only — not investment advice.